Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association
Thomas A. Pearson,George A. Mensah,R. Wayne Alexander,Jeffrey L. Anderson,Richard O. Cannon,Michael H. Criqui,Yazid Y. Fadl,Stephen P. Fortmann,Yuling Hong,Gary L. Myers,Nader Rifai,Sidney C. Smith,Kathryn A. Taubert,Russell P. Tracy,Frank Vinicor +14 more
Reads0
Chats0
TLDR
There has been no consensus from professional societies or governmental agencies as to how these assays of markers of inflammation should be used in clinical practice, and a workshop to address these issues was convened in Atlanta, Ga.Abstract:
In 1998, the American Heart Association convened Prevention Conference V to examine strategies for the identification of high-risk patients who need primary prevention. Among the strategies discussed was the measurement of markers of inflammation.1 The Conference concluded that “many of these markers (including inflammatory markers) are not yet considered applicable for routine risk assessment because of: (1) lack of measurement standardization, (2) lack of consistency in epidemiological findings from prospective studies with endpoints, and (3) lack of evidence that the novel marker adds to risk prediction over and above that already achievable through the use of established risk factors.” The National Cholesterol Education Program Adult Treatment Panel III Guidelines identified these markers as emerging risk factors,1a which could be used as an optional risk factor measurement to adjust estimates of absolute risk obtained using standard risk factors. Since these publications, a large number of peer-reviewed scientific reports have been published relating inflammatory markers to cardiovascular disease (CVD). Several commercial assays for inflammatory markers have become available. As a consequence of the expanding research base and availability of assays, the number of inflammatory marker tests ordered by clinicians for CVD risk prediction has grown rapidly. Despite this, there has been no consensus from professional societies or governmental agencies as to how these assays of markers of inflammation should be used in clinical practice.
On March 14 and 15, 2002, a workshop titled “CDC/AHA Workshop on Inflammatory Markers and Cardiovascular Disease: Applications to Clinical and Public Health Practice” was convened in Atlanta, Ga, to address these issues. The goals of this workshop were to determine which of the currently available tests should be used; what results should be used to define high risk; which patients should be tested; and the indications for which the tests would be most useful. These …read more
Citations
More filters
Journal ArticleDOI
Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Scott M. Grundy,James I. Cleeman,Stephen R. Daniels,Karen A. Donato,Robert H. Eckel,Barry A. Franklin,David Gordon,Ronald M. Krauss,Peter J. Savage,Sidney C. Smith,John A. Spertus,Fernando Costa +11 more
TL;DR: This statement from the American Heart Association and the National Heart, Lung, and Blood Institute is intended to provide up-to-date guidance for professionals on the diagnosis and management of the metabolic syndrome in adults.
Journal ArticleDOI
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Scott M. Grundy,James I. Cleeman,C. Noel Bairey Merz,H. Bryan Brewer,Luther T. Clark,Donald B. Hunninghake,Richard C. Pasternak,Sidney C. Smith,Neil J. Stone +8 more
TL;DR: The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL, and confirm that older persons benefit from therapeutic lowering of LDL-C.
Journal ArticleDOI
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement.
Scott M. Grundy,James I. Cleeman,Stephen R. Daniels,Karen A. Donato,Robert H. Eckel,Barry A. Franklin,David Gordon,Ronald M. Krauss,Peter J. Savage,Sidney C. Smith,John A. Spertus,Fernando Costa +11 more
TL;DR: This statement from the American Heart Association and the National Heart, Lung, and Blood Institute is intended to provide up-to-date guidance for professionals on the diagnosis and management of the metabolic syndrome in adults.
Journal ArticleDOI
The metabolic syndrome
TL;DR: The pathophysiology seems to be largely attributable to insulin resistance with excessive flux of fatty acids implicated, and a proinflammatory state probably contributes to the metabolic syndrome.
Journal ArticleDOI
European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
Joep Perk,G. De Backer,Helmut Gohlke,Ian D. Graham,Zeljko Reiner,Monique Verschuren,Christian Albus,Pascale Benlian,G Boysen,Renata Cifkova,Christi Deaton,Shah Ebrahim,Miles Fisher,Giuseppe Germanò,Richard J. Hobbs,Arno W. Hoes,Sehnaz Karadeniz,Alessandro Mezzani,Eva Prescott,Lars Rydén,Martin Scherer,M Syvänne,Scholte op Reimer Wjm.,Christiaan Vrints,David R. Wood,José Luis Zamorano,Faiez Zannad +26 more
TL;DR: The ESC Guidelines and Expert Consensus Documents as mentioned in this paper summarize and evaluate all currently available evidence on a particular issue with the aim to assist physicians in selecting the best management strategies for a typical patient, suffering from a given condition, taking into account the impact on outcome, as well as the risk-benefit ratio of particular diagnostic or therapeutic means.
References
More filters
Journal ArticleDOI
Users' guides to the medical literature. XVII. How to use guidelines and recommendations about screening
Alexandra Barratt,Les Irwig,Paul Glasziou,Robert G. Cumming,Angela E Raffle,N Hicks,Jam Gray,Gordon H. Guyatt +7 more
TL;DR: It is unsure whether screening relatively young, asymptomatic people at average risk of bowel cancer is likely to do more good than harm, and whether guidelines or recommendations about screening for CRC that might help you are checked.
Journal ArticleDOI
Inflammation in Cardiovascular Disease Cart, Horse, or Both?
TL;DR: The conclusion is that CRP is at least additive to HDL and total cholesterol with respect to risk prediction, and there is some evidence that lipids and CRP are better predictors jointly than would be expected by adding up their individual predictive powers.
Prevention Conference V Beyond Secondary Prevention: Identifying the High-Risk Patient for Primary Prevention Medical Office Assessment
Scott M. Grundy,Terry L. Bazzarre,James I. Cleeman,Martha N. Hill,Nancy Houston-Miller,William B. Kannel,Ronald M. Krauss,Harlan M. Krumholz,Ronald M. Lauer,Ira S. Ockene,Richard C. Pasternak,Thomas A. Pearson,Paul M. Ridker,Darien Wood +13 more
TL;DR: The role of medical office assessment in the detection of risk factors and estimation of total cardiovascular risk was discussed in this article, with the primary focus on identification of known risk factors for coronary heart disease (CHD).
Journal ArticleDOI
Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris
Antonio Giuseppe Rebuzzi,Gaetano Quaranta,Giovanna Liuzzo,Giuseppina Caligiuri,Gaetano Antonio Lanza,J. Ruth Gallimore,R. Grillo,Domenico Cianflone,Luigi M. Biasucci,Attilio Maseri +9 more
TL;DR: In patients with class IIIB unstable angina, among data potentially available on admission, serum levels of troponin T and CRP have a significantly greater prognostic accuracy than symptoms and ECGs.
Journal ArticleDOI
C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease
Trine Madsen,Helle Aarup Skou,Vibeke Ellegaard Hansen,Lars Fog,Jeppe Hagstrup Christensen,Egon Toft,Erik Berg Schmidt +6 more
TL;DR: The inverse correlation between CRP and DHA may reflect an anti-inflammatory effect of DHA in patients with stable coronary arteries disease and suggest a novel mechanism by which fish consumption may decrease the risk of coronary artery disease.
Related Papers (5)
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more